Eli Lilly and Company

The University of North Carolina at Chapel Hill

Shane Krummen Atwell

Stephen John Demarest

Victor H Obungu

Brian Arthur Kuhlman

Andrew Charles Vendel

Hector Aldaz

Karen Jean Froning

Andrew Philip Leaver-Fay

Yiqing Feng

David John Stokell

Songqing Na

Diana Isabel Ruiz

Maya Rachel Karta

Donmienne Leung

Laura Anne Pelletier

The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (C3/C3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.

IgG bispecific antibodies and processes for preparation

The present disclosure relates to antibodies that specifically bind human IL-4Rα, compositions comprising such IL-4Rα antibodies, and methods of using such IL-4Rα antibodies.

Human interleukin-4 receptor alpha antibodies

Antibodies which bind BTLA, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with autoimmune disease including treating lupus.

BTLA agonist antibodies and uses thereof

Growing community of inventors

Carlsbad, CA, United States of America

Shane Krummen Atwell